Klein KR, Wysham C, Tuttle KR, Davies MJ, et al. Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial. Lancet 2026 Sep 30:S0140-6736(26)01865-9. doi: 10.1016/S0140-6736(26)01865.
PMID: 42815506